3407 Asahi Kasei
- 1028.0
- -22.0-2.10%
Asahi Kasei News
Backstage [stocks that moved, stocks that were made]
*Asahi Kasei ＜3407＞ 1028 -22 announced the acquisition of a Swedish pharmaceutical company, so be wary of financial burdens. *Nissanka ＜4021＞ 4534 +100 announced an expansion of the share acquisition quota and an extension of the acquisition period. The upper price is heavy. *Triple Eyes ＜5026＞ 1430+193 Group company Zero Field has opened its 5th domestic data center. *Japan Land Development ＜1887＞ 481-The earnings forecast for the fiscal year ending 1824/5 was revised downward. *Giken Seisakusho ＜6289＞ 1838 +2
RENOVA, TEIJIN, SOMPO, etc
＜4021＞ Nissan 4534 +100 continues to increase drastically. The day before announced the expansion of treasury stock acquisition quotas and the extension of the acquisition period. An announcement of 1.25 million shares, which is 0.90% of the number of issued shares, and a share repurchase with an upper limit of 5 billion yen was made on 5/13, but now, the maximum acquisition limit has been raised to 2.5 million shares or 10 billion yen. The acquisition period used to be from 5/14 to 7/31, but it was changed to 25/3/31. The reason for the change is flexible capital that also takes stock market trends into account
Asahi Kasei Offering to Buy Calliditas Therapeutics for SEK11.8 Billion
Asahi Kasei (TYO:3407) offered to buy Nasdaq-listed drug developer Calliditas Therapeutics in a transaction with a total equity value of 11.8 billion kronor, according to a Tuesday filing with the Tok
Notable stock digest (front field): RENOVA, KOKUSAI, Teijin, etc.
Asahi Kasei ＜3407＞: fell by 1030 yen (-20 yen). The acquisition of Caliditas, a Swedish pharmaceutical company, has been announced. All shares have been acquired through TOB, and it seems that the total acquisition amount is expected to be 173.9 billion yen. Cariditas is developing drugs for kidney disease in the United States and elsewhere. On the company side, it seems that they are aiming for sales of 1 trillion yen in the pharmaceutical and medical device business in fiscal year 30. The final profit and loss of Cariditas for the fiscal year ended 23/12 was in deficit of about 6.8 billion yen, but future sales are expected to expand rapidly
3 points to pay attention to in the front field ~ High-tech led development in response to NVIDIA's drastic rise ~
I would like to pay attention to the following 3 points in the pre-market transaction on the 29th. ■ High-tech-led developments in response to a significant increase in NVIDIA ■ AZEAS, 24/4 downward revised operating income of 291 million yen ← 536 million yen ■ Featured materials from the front: Asahi Kasei, Swedish Pharma acquisitions, expansion of the kidney disease area ■ High-tech-led developments in response to NVIDIA's drastic rise The Japanese stock market on the 29th seems to be a solid market development even though it continues to be at a stalemate. In the US market on the 28th, the NY Dow depreciated by 216 dollars, NASDAQ
Asahi Kasei, Mitsubishi Heavy, etc. [List of brand materials from newspapers]
*NTT ＜9432＞Cable development that can be installed in road surface grooves without the need for utility poles in optical communication networks (Nikkan Kogyo 1 side) - ○*Toyota's ＜7203＞ new engine announced, 4-cylinder 1500cc/2000cc (Nikkan Kogyo 1 side) - ○*SOMPO ＜8630＞ new mid-term plan, ROE raised to 15%, and expanded overseas insurance (Nikkan Kogyo 3 sides) - ○*Asahi Kasei ＜3407＞ acquires Swedish Pharma and expands kidney disease area (Nikkan Kogyo 3 sides) -○*living in the kidney disease area Tomo Corporation ＜8053＞ Entry of offshore wind support ships,
ADR Japan Stock Rankings ~ Takayasu Machimachi, Chicago is 38960 yen, 110 yen higher than Osaka
While Kashima ＜1812＞, AGC ＜5201＞, Hishijisho ＜8802＞, SECOM ＜9735＞, etc. fell in comparison with the Tokyo Stock Exchange (converted to 157.17 yen per dollar), SoftBank G ＜9984＞, ANA ＜9202＞, Ebara ＜6361＞, Shiseido ＜4911＞, etc. rose, and the overall situation was mixed. The Chicago Nikkei 225 futures settlement value is 38,960 yen, which is 110 yen higher than the day in Osaka. The US stock market is mixed. The Dow average is 21
Health Care Stocks Post Broad Decline -- Health Care Roundup
Health-care companies were among the worst performing stocks but remain on pace to post monthly gains. Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights
Deals of the Day-Mergers and Acquisitions
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Maintaining Hold Rating Amidst Calliditas Acquisition by Asahi Kasei: Assessing the Premium Offer and Strategic Fit
Asahi Kasei's Acquisition of Calliditas Therapeutics: A Hold Rating With Revised Price Target
Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug
Calliditas Therapeutics Could Attract Competing Bids -- Market Talk
1220 GMT - Calliditas Therapeutics has received a SEK208 a share bid from Asahi Kasei, and although the price represents an 83% premium to yesterday's close, a higher competing bid can't be ruled out,
Express News | Calliditas Therapeutics Shares Are Trading Higher After the Company's Board Recommended the Acceptance of Asahi Kasei's Tender Offer
Calliditas (CALT.US) surged 70% before the market and was acquired by Asahi Kasei (AHKSY.US) for $1.1 billion
Japanese chemical company Asahi Kasei (AHKSY.US) proposed to buy Swedish biopharmaceutical company Calliditas Therapeutics (CALT.US) for $1.1 billion on Tuesday
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 5/28)
[Good news] ---- ---- ■Tekken Construction [Tokyo Stock Exchange P] will record 2.61 billion yen of profit from the sale of investment securities as special profit for the first quarter of the fiscal year ending 25/3. It has been factored into full-year earnings forecasts. ■Toa Road Industries [Tokyo Stock Exchange P] carried out a stock buyback on the Tokyo Stock Exchange off-site purchase transaction “ToSTNet-3” on the morning of 5/29, with an upper limit of 1 million shares (1.175 billion yen in value), which is 2.13% of the number of issued shares (excluding company shares)
Calliditas Therapeutics' Board Urges Shareholders to Embrace $1.06 Billion Buyout Offer
Calliditas Therapeutics (CALT) said Tuesday its board of directors unanimously recommended that its shareholders accept an 11.16 billion Swedish krona ($1.06 billion) cash buyout offer from Asahi Kase
Asahi Kasei Offers to Buy Calliditas Therapeutics for $1.1B
Press Release: Statement by the Board of Directors of Calliditas Therapeutics AB (Publ) in Relation to the Public Offer by Asahi Kasei Corporation
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation PR Newswire STOCKHOLM, May 28, 2024 STOCKHOLM, May 28, 2024 /PRNe
Analysis
Price Target
No Data
